Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px
Document › Details

Agilent Technologies Inc.. (9/20/24). "Press Release: Agilent Completes Acquisition of Biovectra". Santa Clara, CA.

Region Region Canada
Organisation Organisation Agilent Technologies Inc. (NYSE: A)
Products Product contract manufacturing (drugs)
  Product 2 contract manufacturing (biologicals)
Person Person McDonnell, Padraig (Agilent 202405– CEO before SVP + President CrossLab Group before EVP + GM LifeSAM EMEAI)
     


Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities


Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.

“We are delighted to officially welcome the BIOVECTRA team to Agilent,” said Agilent President and CEO Padraig McDonnell. “This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing.”

With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing. Additional details are available in the news release announcing the acquisition agreement.

Agilent expects the transaction will be $0.05 dilutive to non-GAAP earnings per share (EPS) in the first full year after closing and deliver a double-digit return on invested capital (ROIC) by year five. Agilent funded the transaction using a mix of cash on hand and debt financing.


Additional Information:

FAQs for customers

Highlights for Investors

About Agilent’s Oligonucleotide GMP Manufacturing

About BIOVECTRA


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn and Facebook.


Investor Contact

Parmeet Ahuja
+1 408-345-8948
[email protected]
Media Contact

Sarah Litton
+1 408-361-0405
[email protected]

   
Record changed: 2025-01-14

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Agilent (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top